Antibodies against several podocyte antigens have evolved as markers of diagnosis, disease activity, and prognosis in membranous nephropathy, but their pathogenic role remains debated. Detailed work-up of two cases of primary and secondary membranous nephropathy now supports the concept that thrombospondin type-1 domain-containing 7A autoantibodies are pathogenic.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Urine proteomics of primary membranous nephropathy using nanoscale liquid chromatography tandem mass spectrometry analysis
Clinical Proteomics Open Access 07 February 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hoxha, E. et al. A mechanism for cancer-associated membranous nephropathy. N. Engl. J. Med. 374, 1995–1996 (2016).
Tomas, N. M. et al. Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. J. Clin. Invest. http://dx.doi.org/10.1172/JCI85265 (2016).
Ronco, P. & Debiec, H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. Lancet 385, 1983–1992 (2015).
Debiec, H. et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N. Engl. J. Med. 346, 2053–2060 (2002).
Debiec, H. et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin. N. Engl. J. Med. 364, 2101–2110 (2011).
Beck, L. H. Jr et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361, 11–21 (2009).
Tomas, N. M. et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N. Engl. J. Med. 371, 2277–2287 (2014).
Hoxha, E. et al. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J. Am. Soc. Nephrol. 25, 1357–1366 (2014).
Pani, A. et al. Glomerular diseases and cancer: evaluation of underlying malignancy. J. Nephrol. 29, 143–152 (2016).
Ronco, P. & Debiec, H. Membranous nephropathy: a fairy tale for immunopathologists, nephrologists and patients. Mol. Immunol. 68, 57–62 (2015).
Acknowledgements
The authors thank Pierre Ronco, Pierre et Marie Curie University and Tenon Hospital, Paris, for reviewing the manuscript before submission. H.-J.A. is supported by the European Union's Horizon 2020 research and innovation program under grant agreement No. 668036 (RELENT). The views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Anders, HJ., Ponticelli, C. Membranous nephropathy and the Henle–Koch postulates. Nat Rev Nephrol 12, 447–448 (2016). https://doi.org/10.1038/nrneph.2016.86
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2016.86
This article is cited by
-
Primary membranous nephropathy: an endless story
Journal of Nephrology (2022)
-
Urine proteomics of primary membranous nephropathy using nanoscale liquid chromatography tandem mass spectrometry analysis
Clinical Proteomics (2018)